Core Viewpoint - Zhenghai Biological (300653) announced on September 17 that its active biological bone product is the first domestic bone filling product containing rhBMP-2, which has high innovation potential [1] Company Summary - The active biological bone product is characterized by its specific binding with collagen, indicating a significant innovation in the market [1] - The market share of bone morphogenetic protein (BMP) products in the bone repair materials sector is currently small, suggesting substantial growth potential [1] - The company aims to increase its market share and sales revenue through the unique characteristics of its active biological bone product [1] - Promotion and hospital entry efforts for the active biological bone have been progressing smoothly this year, aligning with expectations [1] - The company plans to enhance the professional promotion capabilities of its sales team to accelerate market expansion [1]

每经AI快讯，9月17日，智飞生物（300122）(300122.SZ)公告称，公司控股子公司宸安生物研发的 CA111注射液获得国家药品监督管理局药物临床试验批准通知书，同意在成人超重或肥胖患者中开展临 床试验。该注射液是一款葡萄糖依赖性胰岛素释放肽(GIP)受体和胰高血糖素样肽-1(GLP-1)受体的双重 激动剂，拥有广阔的市场前景。但需注意的是，药品研发具有投入大、周期长、风险高的特点，且后续 临床试验进度、结果及产品上市情况存在不确定性。 ...

9月17日，君实生物大宗交易成交100万股，成交额4532万元，占当日总成交额的6.05%，成交价45.32 元，较市场收盘价45.64元折价0.7%。 | 025-09-17 | 君实生物 | 688180 | 45.32 4532 | 100 | 方正证券股份有限 公司总部 | 中信证券股份有限 公司上海浦东新区 CALL COLLECT COLLECTION COLLECTION CONSULTER OF CLAINS | 결 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | | 卖出营业部 | 是否为专场 | ...

Core Viewpoint - Rongchang Biopharma (688331.SH) has established a global exclusive licensing agreement with Seattle Genetics (now acquired by Pfizer Inc.) for the development and commercialization rights of RC48 outside of Japan and Singapore, with ongoing clinical trials being conducted by Pfizer as planned [1] Group 1 - The company is actively collaborating with Pfizer to support clinical development and regulatory submissions in overseas markets [1] - Key challenges in the internationalization process include regulatory differences across countries, complex market access policies, and dynamic competitive environments [1]

Core Viewpoint - The company, Zhixiang Jintai (688443.SH), has received approval from the National Medical Products Administration for the clinical trial of its product GR2301 injection, a recombinant fully human anti-IL-15 monoclonal antibody aimed at treating autoimmune diseases like vitiligo caused by IL-15 expression imbalance [1] Group 1 - The clinical trial application for GR2301 injection has been approved, marking a significant milestone for the company [1] - GR2301 injection is designed to inhibit the downstream IAK-STAT signaling pathway by blocking IL-15 interactions, which is crucial for treating autoimmune diseases [1] - As of the announcement date, there are no approved antibody drugs targeting IL-15 globally, indicating a potential market opportunity for the company [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 迈威（上海）生物科技股份有限公司（以下简称"迈威生物"）于2025年9月18日发布公告，宣布调整回 购股份价格上限，旨在保证回购股份方案顺利实施。 回购股份基本情况与实施进展回顾 2025年6月26日，迈威生物第二届董事会第十九次会议审议通过以集中竞价交易方式回购公司已发行的 部分人民币普通股（A股）股份的方案。回购价格不超过35.00元/股（含），回购资金总额不低于2500 万元（含），不超过5000万元（含），回购期限自董事会审议通过本次回购方案之日起12个月内。 8月5日，公司第二届董事会第二十次会议审议通过将回购价格上限调整为48.00元/股（含）。除上述调 整外，回购股份方案的其他内容不变。 本次方案调整符合《中华人民共和国公司法》《上市公司股份回购规则》等相关规定。公司综合考虑证 券市场变化以及股份回购进展等因素，调整后的回购股份价格上限不高于董事会审议通过本次回购股份 方案决议前30个交易日公司股票交易均价的150%，不存在损害公司及全体股东特别是中小投资者权益 的情形。本次仅调整回购股份价格上限，不涉及回购总金额的调整，回购用途未发生变化，不会 ...

Core Viewpoint - The company, Zhixiang Jintai (688443.SH), has received approval from the National Medical Products Administration for the clinical trial of its product GR2301 injection, which is a recombinant fully human anti-IL-15 monoclonal antibody aimed at treating autoimmune diseases like vitiligo caused by IL-15 expression disorders [1] Group 1 - The clinical trial application for GR2301 injection has been approved [1] - GR2301 injection is developed independently by the company [1] - The mechanism of GR2301 involves blocking IL-15 interactions, which may help in treating autoimmune diseases [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of its product GR2301 injection, which is a recombinant fully human anti-IL-15 monoclonal antibody aimed at treating autoimmune diseases like vitiligo caused by IL-15 expression dysregulation [1] Group 1 - The clinical trial application for GR2301 injection has been approved [1] - GR2301 injection is developed independently by the company [1] - The mechanism of GR2301 involves blocking IL-15 from binding to its receptors, thereby inhibiting the downstream IAK-STAT signaling pathway [1]

Core Viewpoint - Shanghai Kehua Bio-engineering Co., Ltd. announced the results of the "Kehua Convertible Bond" repurchase, indicating a low level of investor participation in the repurchase process [1] Group 1: Repurchase Details - The repurchase application period for the "Kehua Convertible Bond" (bond code: 128124) is from September 10 to September 16, 2025 [1] - The repurchase price is set at 100.241 yuan per bond (including interest and tax) [1] - The total number of valid applications received at the end of the application period was 70 bonds, amounting to 7016.87 yuan (including interest and tax) [1] Group 2: Financial Impact - The funds from the issuer will be credited on September 19, with the repurchase amount being allocated on September 22, and investors will receive the funds on September 23 [1] - This repurchase will have no significant impact on the company's financials [1] - The unrepurchased "Kehua Convertible Bonds" will continue to be traded on the Shenzhen Stock Exchange [1]

每经AI快讯，9月17日，迈威生物(688062.SH)公告称，公司与Kalexo Bio,Inc.就2MW7141项目相关签署 《独家许可协议》及《优先股股权购买协议》。根据许可协议，迈威生物许可Kalexo在全球范围独家开 发、生产和商业化以及其他方式开发许可产品的权利。交易金额方面，迈威生物将从Kalexo获得最高可 达10亿美元的预付款和里程碑付款，以及低个位数的特许权使用费，其中包括一次性、不可返还的首付 款及近端付款1,200万美元现金。作为对价的一部分，迈威生物将在符合约定条件下另外获得Kalexo总 计双位数的A轮优先股。此次交易预计将对公司未来业绩产生积极影响，有利于提升公司的盈利能力。 ...